Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.
Antimicrob Agents Chemother
; 62(11)2018 11.
Article
in En
| MEDLINE
| ID: mdl-30181365
ABSTRACT
We evaluated the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) against cefepime-resistant Acinetobacter baumannii strains (n = 13) in the neutropenic murine lung infection model. Twelve isolates were meropenem resistant. In control animals and those that received cefepime or zidebactam alone, the mean bacterial growth at 24 h was >2 log10 CFU/lung compared with 0-h controls (6.32 ± 0.33 log10 CFU/lung). WCK 5222 produced a decline in the bacterial burden for all isolates (mean reduction, -3.34 ± 0.85 log10 CFU/lung) and demonstrated remarkable potency.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Piperidines
/
Carbapenems
/
Cephalosporins
/
Drug Resistance, Multiple, Bacterial
/
Acinetobacter baumannii
/
Cyclooctanes
/
Azabicyclo Compounds
/
Cefepime
/
Lung Diseases
/
Anti-Bacterial Agents
Limits:
Animals
Language:
En
Journal:
Antimicrob Agents Chemother
Year:
2018
Type:
Article
Affiliation country:
United States